GlassScriptPhysician profile
Joseph Chapman
NPI 1619369576
$6,874.24
in general payments reported to CMS, 2019-2025
32 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $278 · 2021: $255 · 2022: $1,149 · 2023: $1,521 · 2024: $1,378 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,329.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,924.97 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $930.88 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $637.89 | 2021-2025 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $414.19 | 2019-2025 | |
| Gilead Sciences, INC. | $255.42 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $253.17 | 2022-2025 | Dupixent |
| Genzyme Corporation | $247.76 | 2022-2025 | |
| Celgene Corporation | $244.34 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $202.31 | 2019-2023 | Ocaliva |
| Lilly USA, LLC | $179.22 | 2023-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.71 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Phathom Pharmaceuticals, INC. | $170.21 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $149.67 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $107.55 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $105.72 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $100.05 | 2022 | |
| Olympus Corporation of The Americas | $95.41 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $89.33 | 2024-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $87.10 | 2019-2023 | Dificid |
| Qol Medical, LLC | $68.43 | 2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $65.57 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $60.87 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $56.80 | 2023-2025 | Rebyota |
| Boston Scientific Corporation | $47.55 | 2024-2025 | Cre Pro |
| Exact Sciences Corporation | $45.67 | 2023 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $45.05 | 2025 | Rezdiffra |
| Alnylam Pharmaceuticals INC. | $21.95 | 2023 | Onpattro |
| Exelixis INC. | $21.23 | 2020 | |
| Novo Nordisk INC | $20.16 | 2025 | Wegovy |
| Amgen INC. | $19.35 | 2023 | Amjevita |
| Shionogi INC | $16.64 | 2019 | |
| Evoke Pharma, INC. | $13.07 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.